vs
Side-by-side financial comparison of Intellicheck, Inc. (IDN) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.6M, roughly 1.4× Intellicheck, Inc.). Intellicheck, Inc. runs the higher net margin — 23.4% vs -60.3%, a 83.7% gap on every dollar of revenue. On growth, Intellicheck, Inc. posted the faster year-over-year revenue change (11.8% vs -49.9%). Intellicheck, Inc. produced more free cash flow last quarter ($2.4M vs $1.6M). Over the past eight quarters, Intellicheck, Inc.'s revenue compounded faster (19.1% CAGR vs -6.7%).
Intellicheck, Inc. is a US-based technology company specializing in identity verification and fraud prevention solutions. It develops AI-powered tools to validate government-issued identification documents, streamline customer onboarding, and mitigate identity theft risks for clients across finance, retail, healthcare and public sector segments.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
IDN vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.6M | $9.1M |
| Net Profit | $1.6M | $-5.5M |
| Gross Margin | 91.4% | 49.4% |
| Operating Margin | 22.5% | -51.1% |
| Net Margin | 23.4% | -60.3% |
| Revenue YoY | 11.8% | -49.9% |
| Net Profit YoY | 218.0% | -184.8% |
| EPS (diluted) | $0.08 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.6M | $9.1M | ||
| Q3 25 | $6.0M | $17.9M | ||
| Q2 25 | $5.1M | $15.7M | ||
| Q1 25 | $4.9M | $10.1M | ||
| Q4 24 | $5.9M | $18.2M | ||
| Q3 24 | $4.7M | $18.0M | ||
| Q2 24 | $4.7M | $13.5M | ||
| Q1 24 | $4.7M | — |
| Q4 25 | $1.6M | $-5.5M | ||
| Q3 25 | $290.0K | $2.4M | ||
| Q2 25 | $-251.0K | $164.0K | ||
| Q1 25 | $-318.0K | $-3.6M | ||
| Q4 24 | $488.0K | $6.5M | ||
| Q3 24 | $-837.0K | $3.2M | ||
| Q2 24 | $-127.0K | $-2.2M | ||
| Q1 24 | $-442.0K | — |
| Q4 25 | 91.4% | 49.4% | ||
| Q3 25 | 90.5% | 53.4% | ||
| Q2 25 | 89.8% | 62.5% | ||
| Q1 25 | 89.7% | 19.1% | ||
| Q4 24 | 91.1% | 78.7% | ||
| Q3 24 | 91.0% | 53.4% | ||
| Q2 24 | 90.5% | 29.8% | ||
| Q1 24 | 90.7% | — |
| Q4 25 | 22.5% | -51.1% | ||
| Q3 25 | 4.0% | 11.9% | ||
| Q2 25 | -5.8% | 7.5% | ||
| Q1 25 | -7.1% | -41.0% | ||
| Q4 24 | 8.1% | 39.6% | ||
| Q3 24 | -19.3% | 22.2% | ||
| Q2 24 | -4.6% | -18.0% | ||
| Q1 24 | -11.2% | — |
| Q4 25 | 23.4% | -60.3% | ||
| Q3 25 | 4.8% | 13.2% | ||
| Q2 25 | -4.9% | 1.0% | ||
| Q1 25 | -6.5% | -35.8% | ||
| Q4 24 | 8.2% | 35.6% | ||
| Q3 24 | -17.8% | 18.0% | ||
| Q2 24 | -2.7% | -16.4% | ||
| Q1 24 | -9.4% | — |
| Q4 25 | $0.08 | $-0.06 | ||
| Q3 25 | $0.01 | $0.03 | ||
| Q2 25 | $-0.01 | $0.00 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $0.02 | $0.10 | ||
| Q3 24 | $-0.04 | $0.03 | ||
| Q2 24 | $-0.01 | $-0.03 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.7M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.7M | $48.2M |
| Total Assets | $24.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.7M | $14.7M | ||
| Q3 25 | $7.2M | $13.6M | ||
| Q2 25 | $8.6M | $17.9M | ||
| Q1 25 | $5.1M | $19.5M | ||
| Q4 24 | $4.7M | $19.8M | ||
| Q3 24 | $5.7M | $27.4M | ||
| Q2 24 | $7.3M | $23.4M | ||
| Q1 24 | $9.2M | — |
| Q4 25 | $20.7M | $48.2M | ||
| Q3 25 | $18.9M | $52.9M | ||
| Q2 25 | $18.0M | $49.9M | ||
| Q1 25 | $17.6M | $45.2M | ||
| Q4 24 | $17.7M | $43.2M | ||
| Q3 24 | $16.7M | $32.4M | ||
| Q2 24 | $17.3M | $28.6M | ||
| Q1 24 | $17.2M | — |
| Q4 25 | $24.5M | $82.3M | ||
| Q3 25 | $25.3M | $82.3M | ||
| Q2 25 | $23.1M | $78.5M | ||
| Q1 25 | $24.6M | $73.9M | ||
| Q4 24 | $20.9M | $73.4M | ||
| Q3 24 | $20.7M | $61.6M | ||
| Q2 24 | $21.9M | $91.5M | ||
| Q1 24 | $22.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.4M | $2.0M |
| Free Cash FlowOCF − Capex | $2.4M | $1.6M |
| FCF MarginFCF / Revenue | 36.0% | 17.8% |
| Capex IntensityCapex / Revenue | 0.1% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.5M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4M | $2.0M | ||
| Q3 25 | $-1.7M | $-3.7M | ||
| Q2 25 | $3.1M | $-5.2M | ||
| Q1 25 | $750.0K | $-5.1M | ||
| Q4 24 | $-1.3M | $4.0M | ||
| Q3 24 | $-1.1M | $4.1M | ||
| Q2 24 | $-1.2M | $-3.6M | ||
| Q1 24 | $869.0K | — |
| Q4 25 | $2.4M | $1.6M | ||
| Q3 25 | $-1.8M | $-4.2M | ||
| Q2 25 | $3.1M | $-5.7M | ||
| Q1 25 | $741.0K | $-5.4M | ||
| Q4 24 | $-1.3M | $3.6M | ||
| Q3 24 | $-1.1M | $4.0M | ||
| Q2 24 | $-1.2M | $-3.8M | ||
| Q1 24 | $860.0K | — |
| Q4 25 | 36.0% | 17.8% | ||
| Q3 25 | -29.2% | -23.7% | ||
| Q2 25 | 60.9% | -36.2% | ||
| Q1 25 | 15.1% | -53.0% | ||
| Q4 24 | -22.4% | 19.6% | ||
| Q3 24 | -23.1% | 22.4% | ||
| Q2 24 | -25.5% | -28.1% | ||
| Q1 24 | 18.4% | — |
| Q4 25 | 0.1% | 4.4% | ||
| Q3 25 | 0.4% | 2.8% | ||
| Q2 25 | 0.3% | 2.8% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.2% | 1.3% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 1.54× | — | ||
| Q3 25 | -5.99× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.71× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDN
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
